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Safety of tiotropium
Indirect evidence suggests the Respimat inhaler is riskier than the Handihaler
Christopher J Cates senior clinical research fellow
St George’s University of London, London, SW17 0RE, UK
Tiotropium is used to treat chronic obstructive pulmonary
disease via two different inhaler devices: the original Handihaler
(18 µg once daily), which uses a powder formulation, and the
newer Respimat mist inhaler (5 µg once daily). The two devices
cannot be assumed to have the same safety profile, however,
and the linked systematic review by Singh and colleagues
(doi:10.1136/bmj.d3215) assessed all cause mortality in people
with chronic obstructive pulmonary disease using the Respimat
mist inhaler.1
An ongoing trial will provide more certainty about the
comparative safety of tiotroprium inhaler devices
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The authors assessed the risk of all doses of tiotropium given
via the mist inhaler (including 10 µg daily), but because the
usual dose in clinical practice is 5 µg daily, this editorial will
focus on the safety results for this dose only. The review
reported a 46% relative increase in risk of mortality from any
cause in patients using the mist inhaler compared with placebo
(relative risk 1.46, 95% confidence interval 1.01 to 2.10).
Relative risks and odds ratios are used in meta-analyses because
they tend to be more stable across trials of different durations
and with participants at different baseline risks. However, it is
misleading to describe the effect as a 46% increased risk of
dying.
The impact of the relative risk depends on the baseline risk of
the patient concerned. In this case, in trials that lasted for a year,
47 of 2655 participants taking placebo died, which gives a
mortality risk of 1.8% a year. In the same trials, 68 of the 2659
participants taking 5 µg of tiotropium via the mist inhaler died,
which gives a mortality risk of 2.6% a year. The 46% relative
increase in risk therefore represents an absolute difference of
0.8%, because death was a rare event. The difference in absolute
risk is shown in the Cates plot (www.nntonline.net/visualrx/
cates_plot/; figure), in which 18 deaths occurred in the trials for
each 1000 patients treated for a year with placebo, and an extra
eight occurred in those treated with tiotropium via the mist
inhaler. This translates into an annual number needed to treat
for one additional participant to suffer harm (NNT(H)) of 121
patients given 5 µg tiotropium for a year for one additional death
compared with patients given placebo. There is considerable
uncertainty around this estimate, and the 95% confidence
interval runs from anywhere between NNT(H) of 51 and 5556.
However, this point estimate of the increased risk of mortality
with the mist inhaler is considerably larger than that found for
salmeterol in asthma (7/10 000 over 28 weeks).2
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So how do we go about sharing this risk information with
patients? What we really want to know is how the risk of the
Respimat compares with that of the Handihaler. Although the
UPLIFT trial did not report an increase in mortality in patients
using the Handihaler, that trial differed greatly from those that
looked at the Respimat, so differences between the delivery
devices cannot be untangled from other differences between the
trials.3 More certainty about the comparative safety of the two
devices will have to wait for the results of the ongoing
randomised trial mentioned by Singh and colleagues,4 which
directly compares tiotropium delivered by the Handihaler (18
µg a day) or the Respimat (5 µg and 2.5 µg a day).
The improved delivery afforded by the mist inhaler could
possibly increase plasma concentrations of tiotropium and
therefore increase risks. Could the excess mortality in the
Respimat trials be caused by the inclusion of patients who are
taking 10 µg a day? This is unlikely, because risk in patients
taking the 5 µg dose was still significantly increased. The
Medicines andHealthcare Products RegulatoryAgency currently
advises caution when using the mist inhaler in patients with
arrhythmias and that the recommended daily dose should not
be exceeded.5
So where do we go from here? Pending the results of the head
to head trial, the indirect evidence that is currently available
suggests that the Handihaler is a safer bet than the Respimat. If
patients have a strong preference for the mist inhaler, the
possible increased risk in mortality will need to be shared with
them, and the Cates plot might help to make this easier.
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• “Obtaining a clinically significant difference in these trials
is like winning an Olympic medal with statistical
significance the equivalent of finishing fourth or fifth.” R
Andrew McIvor, professor of medicine, McMaster
University,Hamilton, Ontario, Canada
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